Wedbush Initiates Coverage On Oruka Therapeutics with Outperform Rating, Announces Price Target of $40
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst David Nierengarten has initiated coverage on Oruka Therapeutics with an Outperform rating and set a price target of $40.
September 04, 2024 | 3:34 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush has initiated coverage on Oruka Therapeutics with an Outperform rating and a price target of $40, indicating a positive outlook for the stock.
The initiation of coverage with an Outperform rating and a $40 price target by Wedbush suggests a positive sentiment towards Oruka Therapeutics. This is likely to boost investor confidence and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100